Patents by Inventor Markus Böhringer
Markus Böhringer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120122854Abstract: The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: ApplicationFiled: January 11, 2012Publication date: May 17, 2012Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Narendra Panday, Fabienne Ricklin, Martin Stahl, Petra Schmitz
-
Patent number: 7803819Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: July 17, 2007Date of Patent: September 28, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Publication number: 20100222340Abstract: The present invention relates to compounds of formula (I) wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: ApplicationFiled: May 13, 2010Publication date: September 2, 2010Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Fabienne Ricklin, Hans Peter Wessel
-
Patent number: 7718666Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: June 17, 2004Date of Patent: May 18, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
-
Patent number: 7718659Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb)??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: GrantFiled: February 4, 2008Date of Patent: May 18, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
-
Publication number: 20100087485Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.Type: ApplicationFiled: December 9, 2009Publication date: April 8, 2010Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
-
Patent number: 7683079Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.Type: GrantFiled: December 14, 2005Date of Patent: March 23, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
-
Publication number: 20090270360Abstract: The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, Rc, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: ApplicationFiled: January 16, 2009Publication date: October 29, 2009Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Roland Humm, Hans Iding, Dietmar Knopp, Narendra Panday, Fabienne Ricklin, Christoph Martin Stahl
-
Patent number: 7501413Abstract: The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, Rc, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: GrantFiled: October 31, 2005Date of Patent: March 10, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Roland Humm, Hans Iding, Dietmar Knopp, Narendra Panday, Fabienne Ricklin, Christoph Martin Stahl
-
Patent number: 7417144Abstract: The invention is concerned with novel heteroaryl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments.Type: GrantFiled: July 7, 2006Date of Patent: August 26, 2008Assignee: Hoffman-La Roche Inc.Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
-
Patent number: 7411093Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: December 13, 2005Date of Patent: August 12, 2008Assignee: Hoffman-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Hans Peter Marty, Patrizio Mattei, Robert Narquizian
-
Publication number: 20080146550Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) R—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb) ??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: ApplicationFiled: February 4, 2008Publication date: June 19, 2008Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
-
Patent number: 7361672Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb)??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: GrantFiled: December 13, 2005Date of Patent: April 22, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
-
Patent number: 7348349Abstract: The present invention relates to compounds of formula (I) wherein wherein R1, R2, R3, R4, R5, R6 and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases (such as e.g. crown disease, inflammatory bowel disease, collitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function) and proliferative diseases.Type: GrantFiled: July 18, 2005Date of Patent: March 25, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Markus Boehringer, Uwe Grether, Hans Hilpert, Georges Hirth, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Fabienne Ricklin
-
Patent number: 7314884Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: December 13, 2004Date of Patent: January 1, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Publication number: 20070259925Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: ApplicationFiled: July 17, 2007Publication date: November 8, 2007Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Publication number: 20070112012Abstract: The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: ApplicationFiled: November 1, 2006Publication date: May 17, 2007Inventors: Markus Boehringer, Katrin Zbinden, Wolfgang Haap, Narendra Panday, Fabienne Ricklin, Martin Stahl, Petra Schmitz
-
Publication number: 20070015812Abstract: The invention is concerned with novel heteroaryl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments.Type: ApplicationFiled: July 7, 2006Publication date: January 18, 2007Inventors: Markus Boehringer, Katrin Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
-
Patent number: 7122555Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: June 17, 2004Date of Patent: October 17, 2006Assignee: Hoffmann-la Roche Inc.Inventors: Markus Boehringer, Bernd Kuhn, Patrizio Mattei, Robert Narquizian
-
Publication number: 20060142362Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb) ??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: ApplicationFiled: December 13, 2005Publication date: June 29, 2006Inventors: Markus Boehringer, Katrin Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin